Tiffany, Kors to Re...
Health Care: Drugs
MediciNova Inc. (MNOV: NASDAQ)
$3.14 -0.03 | -0.95%
05/24/13 - 04:00 PM ET
23.20K / 183.20K
Vol / Avg. Vol:3.15 / 3.17
Open / Prev. Close:3.07 - 3.20
Today's Range:1.29 - 4.70
52 Wk Range:93.29%
Performance YTD:TheStreet Rating:
Portfolios with MNOV
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserStock rocks!
- Contributor9 Health Care Stocks With 1...
- Contributor5 Health Care Stocks With U...
- Contributor10 Pharma Stocks With 100% ...
- Contributor$5 Stocks That Analysts Exp...
- UserBarron's Insider Purchases ...
Latest MNOV Headlines from TheStreet
- MediciNova Reports Fourth Quarter And Full Year 2012 Results 03.28.13 | 05:03 pm
- MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal And Analgesia Data Presentation At The American Academy Of Neurology Annual Meeting 03.20.13 | 07:03 pm
- FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For The Treatment Of Methamphetamine Dependence 02.25.13 | 06:02 pm
- MediciNova Provides Development Update 01.03.13 | 06:01 pm
- MediciNova Meets With FDA For End-of-Phase 2 Meeting For MN-221 For The Treatment Of Acute Exacerbations Of Asthma 10.22.12 | 07:10 pm
- NIH Funds UCLA Phase 2 Study Of MediciNova's MN-166 In Treating Drug Addiction 09.04.12 | 07:09 pm
- MediciNova To Present At The Rodman & Renshaw Annual Global Investment Conference On September 11, 2012 08.28.12 | 07:08 pm
- MediciNova Announces Positive Preliminary Results From A Multi-Day, Repeat-Dose Clinical Trial With MN-221 In Chronic Obstructive Pulmonary Disease Patients 08.23.12 | 07:08 pm
- MediciNova Enters Into A $20 Million Common Stock Purchase Agreement With Aspire Capital Fund 08.20.12 | 07:08 pm
- MediciNova Reports Second Quarter 2012 Results 08.09.12 | 07:08 pm
Press Releases for MNOV
- MediciNova Releases Notice Of Pendency And Settlement Of Class Action - Business Wire 04.23.10 | 04:04 pm
Partner Headlines for MNOV
- Positive Data on MediciNova's MN-221 - Analyst Blog - NASDAQ 08.24.12 | 09:08 pm
- Positive Data on MediciNova's MN-221 - Analyst Blog - Zacks 08.24.12 | 06:08 pm
- Benzinga's Microcap Movers for Tuesday July 3, 2012 - Benzinga 07.04.12 | 01:07 pm
- Morning Market Movers - Benzinga 07.03.12 | 09:07 am
- Must Know Stock Upgrades and Downgrades Today - Wall St. Cheat Sheet 05.24.12 | 03:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical Trial Results Soon - Benzinga 04.19.12 | 01:04 pm
- Global Hunter Initiates Coverage of MediciNova with Speculative Buy and PT of $4 - Benzinga 06.22.11 | 09:06 am
- Company News for March 25,2011 - Corporate Summary - Zacks 03.25.11 | 10:03 am
- Morning Market Losers (MNOV, IRDMW, PCE, SCHL) - Benzinga 03.24.11 | 09:03 am
